Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 1/2 3Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 14Other solid neoplasm 9Thoracic 8Dermatologic 8Head & Neck 5Gynecologic 5Breast 4Tumor-Agnostic 3Sarcoma 3Genitourinary 3CNS 2Lymphoid 1Endocrine 1

Conditions

Neoplasms 3

Interventions

pembrolizumab 18Nivolumab 18Gemcitabine 9Ipilimumab 8Cisplatin 8Carboplatin 8Capecitabine 8Paclitaxel 6Cetuximab 6atezolizumab 5Irinotecan 5Docetaxel 5Cyclophosphamide 5Bevacizumab 5avelumab 4Trastuzumab 4Fluorouracil 4trametinib 3spartalizumab 3Specimen Handling 3Pemetrexed 3Leucovorin 3Everolimus 3Dexamethasone 3Biopsy 3urelumab 2toripalimab 2tislelizumab 2ribociclib 2repotrectinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × spartalizumab × Tumor-Agnostic × Clear all
NCT04669899 2024-04-09

Study of JTX-8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors

Jounce Therapeutics, Inc.

Phase 1/2 Completed
190 enrolled
Tumor-Agnostic

Neoplasms

NCT01714739 2023-02-02

A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Completed
337 enrolled 42 charts
Tumor-Agnostic

Neoplasms

NCT03351231 2020-08-26

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer

Bristol-Myers Squibb

Phase 1/2 Terminated
7 enrolled 6 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡